ClinicalTrials.gg
RecruitingNCT06361888Updated Sep 17, 2026

A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer

A Phase 2/3 interventional study of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine and Nab-paclitaxel Plus Gemcitabine in Metastatic Pancreatic Cancer, sponsored by Hutchmed. Recruiting at 52 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-17.

Sponsored by Hutchmed · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
502
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 630 studies in Pancreatic Neoplasms with a site in China — 334 open to participants now, 360 under way, 30 of them phase 3. Pancreatic Neoplasms · China.

Planned enrollment
36th of 508
502 · median 58
Started
2024
with 107 others
Phase 2/3
13 of 630
7 open now
Primary completion
2028-05
later than 306 of 359 live
Registered
380th of 630
by date

Among the 630 studies in Pancreatic Neoplasms with a site in China, this one is the 36th largest by planned enrollment of the 508 interventional ones that give a count, is one of 108 that started in 2024, is one of 13 in phase 2/3, reaches primary completion later than 306 of the 359 other live ones, and was the 380th registered.

Pancreatic Neoplasms

3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,003 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

334 of the 630 studies in Pancreatic Neoplasms with a site in China are open now. Recruiting first, the newest first:

329 more — sign in →

All 334 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 477 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 630 studies in Pancreatic Neoplasms with a site in China, or all of them as a file.
02

Study summary

To evaluate the efficacy of surufatinib combined with camrelizumab, nab-paclitaxel, and gemcitabine versus nab-paclitaxel plus gemcitabine as the first-line treatment in metastatic pancreatic cancer

Read the detailed description

This is a multicenter, randomized, open-label, active-controlled, phase II/III trial to evaluate the efficacy and safety of surufatinib combined with camrelizumab, nab-paclitaxel, and gemcitabine versus nab-paclitaxel plus gemcitabine as the first-line treatment in metastatic pancreatic cancer

03

Conditions studied

  • Metastatic Pancreatic Cancer

Keywords

  • First-line treatment in patients
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Fully understand and voluntarily sign an form, willing and able to follow the study process;
  2. Age range is 18-75 years old (inclusive);
  3. Pancreatic cancer confirmed by histology or cytology;
  4. Stage IV Pancreatic cancer patients;
  5. Have not received previous systematic anti-tumor treatment in the stage of metastatic pancreatic cancer;
  6. According to 1.1, there is at least one ;
  7. (ECOG) Performance Status score of 0 or 1;
  8. Expected survival time ≥ 12 weeks;

Exclusion criteria

Exclusion Criteria:

  1. Use of systematic non-specific immunomodulatory therapy within 2weeks prior to the first dose;
  2. Presence of other in the past 5 years;
  3. Received major surgical surgery within 4 weeks before the first dose;
  4. Received palliative radiotherapy within 1 week before the first dose; received radical radiotherapy within 4 weeks before the first dose;
  5. Any known allergy to surufatinib or its components, camrelizumab, nab-paclitaxel, or gemcitabine;
  6. Received strong-inducers or strong-inhibitors of cytochrome P450 (CYP) 3A within 2 weeks or 5 half-lives (whichever is longer) before the first dose;
  7. Use of drugs within 4 weeks before first dose;
  8. Known history of liver disease, including active viral hepatitis infection or other active hepatitis or clinically significant moderate to severe cirrhosis;
  9. Patients who currently have hypertension that cannot be controlled by medication;
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
502 participants (estimated)

Study arms

  • Experimental
    Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine

    Drug: Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine

  • Active comparator
    Nab-paclitaxel Plus Gemcitabine

    Drug: Nab-paclitaxel Plus Gemcitabine

  • Other
    Surufatinib with Nab-paclitaxel, and Gemcitabine

    Drug: Surufatinib with Nab-paclitaxel, and Gemcitabine

Interventions

  • DrugSurufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine

    Drug: Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine 1. Surufatinib: 200mg, qd 2. Camrelizumab: 200mg, IV drip, Q3W, D1 3. Nab-paclitaxel: 125 mg/m2, IV drip, D1,D8 4. Gemcitabine : 1000 mg/m2, IV drip, D1, D8

  • DrugNab-paclitaxel Plus Gemcitabine

    Drug pages: Albumin-Bound Paclitaxel · Gemcitabine

    Drug: Nab-paclitaxel Plus Gemcitabine 1. Nab-paclitaxel: 125 mg/m2, IV drip, D1,D8 2. Gemcitabine : 1000 mg/m2, IV drip, D1, D8

  • DrugSurufatinib with Nab-paclitaxel, and Gemcitabine

    Drug: Surufatinib with Nab-paclitaxel, and Gemcitabine 1. Surufatinib: 200mg, qd 2. Nab-paclitaxel: 125 mg/m2, IV drip, D1,D8 3. Gemcitabine : 1000 mg/m2, IV drip, D1, D8

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Duration from the date of initial treatment to the date of death due to any cause

    Time frame: From date of first dose of study drug until withdrawal of consent or death (up to approximately 20 months)

Secondary outcomes

  1. Progression-free Survival (PFS) (RECIST1.1)

    A duration from the date of initial treatment to disease progression or death of any cause.

    Time frame: From date of first dose of study drug until disease progression, withdrawal of consent, death, new anticancer therapy (up to approximately 20 months)

  2. Objective response rate (ORR)(RECIST1.1)

    The incidence of confirmed complete response or partial response

    Time frame: From date of first dose of study drug until disease progression, withdrawal of consent, death, new anticancer therapy (up to approximately 20 months)

  3. Duration of response (DoR)(RECIST1.1)

    Duration from the first time reported partial response or complete response to the first time of disease progression or death.

    Time frame: From date of first dose of study drug until disease progression, withdrawal of consent, death, new anticancer therapy (up to approximately 20 months)

  4. Disease control rate (DCR)(RECIST1.1)

    Proportion of patients whose tumor volume control (reduced or enlarged) reaches a predetermined value and can maintain a minimum time limit.

    Time frame: From date of first dose of study drug until disease progression, withdrawal of consent, death, new anticancer therapy (up to approximately 20 months)

  5. Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30)(only for phase III)

    The changes in health-related quality of life (HRQoL) score from baseline and the time to deterioration of symptoms (TTD) as assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire \- Core 30 (EORTC QLQ-C30)

    Time frame: From the within 7 days prior to the initiation of treatment to 30 days after the last administration

  6. Cancer Quality of Life Questionnaire - PAN26(EORTC QLQ-PAN26)(only for phase III)

    The changes in health-related quality of life (HRQoL) score from baseline and thehe time to deterioration of symptoms (TTD) as assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire \- PAN26 (EORTC QLQ-PAN26)

    Time frame: From the within 7 days prior to the initiation of treatment to 30 days after the last administration

07

Study locations

52 of 52 sites recruiting
  • Anhui Provincial Hospital
    Hefei, Anhui, China
    Recruiting
    • Yueyin Pan · Contact
    • Yueyin Pan · Principal investigator
  • Beijing Cancer Hospital
    Beijing, Beijing Municipality, China
    Recruiting
    • Chunyi Hao · Contact
    • Chunyi Hao · Principal investigator
  • Peking Union Medical College Hospital
    Beijing, Beijing Municipality, China
    Recruiting
    • Xiang Wang · Contact
    • Xiang Wang · Principal investigator
  • Peking University Third Hospital
    Beijing, Beijing Municipality, China
    Recruiting
    • Chunhui Yuan · Contact
    • Chunhui Yuan · Principal investigator
  • Chongqing General Hospital
    Chongqing, Chongqing Municipality, China
    Recruiting
    • Zhibin Luo · Contact
    • Zhibin Luo · Principal investigator
  • Chongqing University Cancer Hospital
    Chongqing, Chongqing Municipality, China
    Recruiting
    • Yi Gong · Contact
    • Yi Gong · Principal investigator
    • Dewei Li · Principal investigator
  • Fujian Cancer Hospital
    Fuzhou, Fujian, China
    Recruiting
    • Sha Huang · Contact
    • Sha Huang · Principal investigator
  • The First Affiliated Hospital of Xiamen University
    Xiamen, Fujian, China
    Recruiting
    • Jianbo Chen · Contact
    • Jianbo Chen · Principal investigator
  • Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center
    Shenzhen, Guangdong, China
    Recruiting
    • Ying Wang · Contact
    • Ying Wang · Principal investigator
  • The First Affiliated Hospital of Guangxi Medical University
    Nanning, Guangxi, China
    Recruiting
    • Jie Ma · Contact
    • Jie Ma · Principal investigator
  • Guangdong Provincial People's Hospital
    Guandong, Guangzhou, China
    Recruiting
    • Rufu Chen · Contact
    • Rufu Chen · Principal investigator
  • Hainan General Hospital
    Haikou, Hainan, China
    Recruiting
    • Jinfang Zheng · Contact
    • Jinfang Zheng · Principal investigator
  • First Hospital of Qinhuangdao
    Qinhuangdao, Hebei, China
    Recruiting
    • Liming Gao · Contact
    • Liming Gao · Principal investigator
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang, China
    Recruiting
    • Yanqiao Zhang · Contact
    • Yanqiao Zhang · Principal investigator
  • Anyang Cancer Hospital
    Anyang, Henan, China
    Recruiting
    • Jin Xia · Contact
    • Jin Xia · Principal investigator
  • The First Affiliated Hospital of Henan Medical University
    Xinxiang, Henan, China
    Recruiting
    • Yinghua Ji · Contact
    • Yinghua Ji · Principal investigator
  • Henan Cancer Hospital
    Zhengzhou, Henan, China
    Recruiting
    • Xiaobing Chen · Contact
    • Xiaobing Chen · Principal investigator
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan, China
    Recruiting
    • Yanru Qin · Contact
    • Yanru Qin · Principal investigator
  • Hubei Cancer Hospital
    Wuhan, Hubei, China
    Recruiting
    • Dongde Wu · Contact
    • Dongde Wu · Principal investigator
  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei, China
    Recruiting
    • Xianglin Yuan · Contact
    • Xianglin Yuan · Principal investigator
  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei, China
    Recruiting
    • Heshui Wu · Contact
  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei, China
    Recruiting
    • Tao Zhang · Contact
    • Tao Zhang · Principal investigator
  • Hunan Cancer Hospital
    Changsha, Hunan, China
    Recruiting
    • Zhenyang Liu · Contact
    • Zhenyang Liu · Principal investigator
  • XiangYa Hospital CentralSouth University
    Changsha, Hunan, China
    Recruiting
    • Xuejun Gong · Contact
    • Xuejun Gong · Principal investigator
  • Jiangsu Cancer Hospital
    Nanjing, Jiangsu, China
    Recruiting
    • Huayun Zhu · Contact
    • Huayun Zhu · Principal investigator
  • Nanjing Drum Tower Hospital
    Nanjing, Jiangsu, China
    Recruiting
    • Juan Du · Contact
    • Juan Du · Principal investigator
  • Nanjing Tianyinshan Hospital
    Nanjing, Jiangsu, China
    Recruiting
    • Shukui Qin · Contact
    • Chen Xun · Principal investigator
  • Nantong Cancer Hospital
    Nantong, Jiangsu, China
    Recruiting
    • Aibing Xu · Contact
    • Aibing Xu · Principal investigator
  • The First Affiliated Hospital of Soochow University
    Suzhou, Jiangsu, China
    Recruiting
    • Wei Li · Contact
    • Wei Li · Principal investigator
  • Jiangyin People's Hospital
    Wuxi, Jiangsu, China
    Recruiting
    • Lichun Deng · Contact
    • Lichun Deng · Principal investigator
  • Jiangxi Cancer Hospital
    Nanchang, Jiangxi, China
    Recruiting
    • Huiqing Zhang · Contact
    • Huiqin Zhang · Principal investigator
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi, China
    Recruiting
    • Yong Li · Contact
    • Yong Li · Principal investigator
  • Jilin Cancer Hospital
    Changchun, Jilin, China
    Recruiting
    • Xueying Zhang · Contact
    • Xueying Zhang · Principal investigator
  • Liaoning Cancer Hospital
    Shenyang, Liaoning, China
    Recruiting
    • Xiangdong Hua · Contact
    • Xiangdong Hua · Principal investigator
  • The First Hospital of China Medical University
    Shenyang, Liaoning, China
    Recruiting
    • Xiujuan Qu · Contact
    • Xiujuan Qu · Principal investigator
  • Shandong Cancer Hospital
    Jinan, Shandong, China
    Recruiting
    • He Tian · Contact
    • He Tian · Principal investigator
    • Yuping Sun · Principal investigator
  • Affiliated Hospital Of Jining Medical University
    Jining, Shandong, China
    Recruiting
    • Junye Wang · Contact
  • Linyi People's Hospital
    Linyi, Shandong, China
    Recruiting
    • Zhongmin Zhang · Contact
    • Zhongmin Zhang · Principal investigator
  • Huashan Hospital, Fudan University
    Shanghai, Shanghai Municipality, China
    Recruiting
    • Deliang Fu · Contact
    • Deliang Fu · Principal investigator
  • Ruijin Hospital, Shanghai Jiaotong University School of Medicine
    Shanghai, Shanghai Municipality, China
    Recruiting
    • Boyong Shen · Contact
    • Boyong Shen · Principal investigator
  • ZhongShan Hospital Fudan University
    Shanghai, Shanghai Municipality, China
    Recruiting
    • Liang Liu · Contact
    • Liang Liu · Principal investigator
  • Shanxi Provincial Cancer Hospitial
    Taiyuan, Shanxi, China
    Recruiting
    • Wenhui Yang · Contact
    • Wenhui Yang · Principal investigator
  • The First Affiliated Hospital of Xi'an Jiaotong University
    Xi’an, Shanxi, China
    Recruiting
    • Enxiao Li · Contact
    • Enxiao Li · Principal investigator
  • Sichuan Cancer Hospital
    Chengdu, Sichuan, China
    Recruiting
    • Haiqing Wang · Contact
    • Haiqing Wang · Principal investigator
  • West China Hospital of Sichuan University
    Chengdu, Sichuan, China
    Recruiting
    • Dan Cao · Contact
    • Dan Cao · Principal investigator
  • Tianjin Cancer Hospital Airport Hospital
    Tianjin, Tianjin Municipality, China
    Recruiting
    • Huikai Li · Contact
    • Huikai Li · Principal investigator
  • Tianjin Cancer Hospital
    Tianjin, Tianjin Municipality, China
    Recruiting
    • Jihui Hao · Contact
    • Jihui Hao · Principal investigator
  • Yunnan Cancer Hospital
    Kunming, Yunnan, China
    Recruiting
    • Lin Xie · Contact
    • Lin Xie · Principal investigator
  • The Second Affiliated Hospital Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
    Recruiting
    • Jiaqi Chen · Contact
    • Jiaqi Chen · Principal investigator
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang, China
    Recruiting
    • Qi Xu · Contact
    • Qi Xu · Principal investigator
  • Zhejiang Provincial People's Hospital
    Hangzhou, Zhejiang, China
    Recruiting
    • Yiping Mou · Contact
    • Yiping Mou · Principal investigator
  • The First Affiliated Hospital of Wenzhou Medical University
    Wenzhou, Zhejiang, China
    Recruiting
    • Hongwei Sun · Contact
    • Hongwei Sun · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2024 (actual). Primary completion is estimated for May 2028, 48 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2024
First posted
Apr 12, 2024
StartActual
May 8, 2024
Primary completionEst.
May 31, 2028
CompletionEst.
May 31, 2028
Last update
Sep 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06361888
Lead sponsor
Hutchmed
Responsible party
Sponsor
First posted
Apr 12, 2024
Start date
May 8, 2024
Primary completion
May 31, 2028 (estimated)
Completion
May 31, 2028 (estimated)
Last update
Sep 17, 2026

Study contacts

Panfeng Tan
Contact
panfengt@hutch-med.com
+86 21 20671828
Shukui Qin
principal investigator · Nanjing Tianyinshan Hospital
Jihui Hao
principal investigator · Tianjin Cancer Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion